Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26907846 | 0.87 | KCNMA1 (0.37) | SMOKCNMA1RXRAPPARGRAB9A | |
| SCHEMBL26907967 | 0.85 | KCNMA1 (0.41) | SMOKCNMA1RAB9A | |
| SCHEMBL26907939 | 0.84 | MAPT (0.35) | SMORAB9A | |
| SCHEMBL29769992 | 0.83 | MAOB (0.36) | MAOBPIM1ESR1ESR2KCNMA1 | |
| SCHEMBL27117654 | 0.83 | MAOB (0.36) | MAOBPIM1ESR1ESR2KCNMA1 | |
| SCHEMBL26907934 | 0.82 | SMN1; SMN2 (0.34) | PIM1 | |
| SCHEMBL26907881 | 0.82 | MAPT (0.37) | SMORXRAS1PR3 | |
| SCHEMBL26907842 | 0.81 | S1PR3 (0.35) | SMOS1PR3 | |
| SCHEMBL26907921 | 0.81 | CHRM4 (0.36) | SMOMAOBRAB9A | |
| SCHEMBL26907931 | 0.80 | CHRM4 (0.37) | MAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-04-11 | — | — | US | claimed |
| EP-4286374-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | Txinno Bioscience Inc. (KR) | 2023-12-06 | — | — | EP | claimed |
| CN-116724026-A | Novel benzotriazole derivatives having inhibitory activity against dinucleotide pyrophosphatase-phosphodiesterase and use thereof | 谛希诺生物科技有限公司 | 2023-09-08 | — | — | CN | claimed |
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2024-04-11 | — | — | US | disclosed |
| EP-4286374-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | Txinno Bioscience Inc. (KR) | 2023-12-06 | — | — | EP | disclosed |
| CN-116724026-A | Novel benzotriazole derivatives having inhibitory activity against dinucleotide pyrophosphatase-phosphodiesterase and use thereof | 谛希诺生物科技有限公司 | 2023-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116882-A1 | NOVEL BENZOTRIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE, AND USE THEREOF | ENPP1, ENPP3, TPP1 | SMO 4146/4885MAOB 1265/4885PIM1 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.